NCT00818454 - 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma | Biotech Hunter

Enrollment

226

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

September 30, 2009

Conditions

Asthma

Interventions

DRUG

Combivent CFC MDI

DRUG

Albuterol HFA MDI

DRUG

Respimat Combivent

Trial Locations (41)

Unknown

1012.57.121 Boehringer Ingelheim Investigational Site, Birmingham

1012.57.144 Boehringer Ingelheim Investigational Site, Los Angeles

1012.57.145 Boehringer Ingelheim Investigational Site, Los Angeles

1012.57.124 Boehringer Ingelheim Investigational Site, Palmdale

1012.57.137 Boehringer Ingelheim Investigational Site, San Diego

1012.57.130 Boehringer Ingelheim Investigational Site, Stockton

1012.57.134 Boehringer Ingelheim Investigational Site, Centennial

1012.57.151 Boehringer Ingelheim Investigational Site, Wheat Ridge

1012.57.119 Boehringer Ingelheim Investigational Site, Panama City

1012.57.149 Boehringer Ingelheim Investigational Site, Winter Park

1012.57.104 Boehringer Ingelheim Investigational Site, Augusta

1012.57.107 Boehringer Ingelheim Investigational Site, Coeur d'Alene

1012.57.127 Boehringer Ingelheim Investigational Site, Normal

1012.57.140 Boehringer Ingelheim Investigational Site, Louisville

1012.57.143 Boehringer Ingelheim Investigational Site, Baltimore

1012.57.126 Boehringer Ingelheim Investigational Site, North Dartmouth

1012.57.147 Boehringer Ingelheim Investigational Site, North Dartmouth

1012.57.113 Boehringer Ingelheim Investigational Site, Minneapolis

1012.57.131 Boehringer Ingelheim Investigational Site, Plymouth

1012.57.116 Boehringer Ingelheim Investigational Site, St Louis

1012.57.146 Boehringer Ingelheim Investigational Site, Bozeman

1012.57.132 Boehringer Ingelheim Investigational Site, Omaha

1012.57.139 Boehringer Ingelheim Investigational Site, Skillman

1012.57.109 Boehringer Ingelheim Investigational Site, Chapel Hill

1012.57.118 Boehringer Ingelheim Investigational Site, Raleigh

1012.57.128 Boehringer Ingelheim Investigational Site, Winston-Salem

1012.57.102 Boehringer Ingelheim Investigational Site, Cincinnati

1012.57.129 Boehringer Ingelheim Investigational Site, Lake Oswego

1012.57.138 Boehringer Ingelheim Investigational Site, Portland

1012.57.108 Boehringer Ingelheim Investigational Site, Hershey

1012.57.114 Boehringer Ingelheim Investigational Site, Philadelphia

1012.57.111 Boehringer Ingelheim Investigational Site, Upland

1012.57.142 Boehringer Ingelheim Investigational Site, Easley

1012.57.117 Boehringer Ingelheim Investigational Site, Greenville

1012.57.103 Boehringer Ingelheim Investigational Site, Union

1012.57.136 Boehringer Ingelheim Investigational Site, El Paso

1012.57.148 Boehringer Ingelheim Investigational Site, Killeen

1012.57.101 Boehringer Ingelheim Investigational Site, San Antonio

1012.57.141 Boehringer Ingelheim Investigational Site, Seattle

1012.57.150 Boehringer Ingelheim Investigational Site, Tacoma

1012.57.105 Boehringer Ingelheim Investigational Site, Madison